Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.
Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.
复制标题
DOI：
10.2147/dddt.s135571
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Zhan J
中科院分区：
文献类型：
--
作者：
Kalim M;Chen J;Wang S;Lin C;Ullah S;Liang K;Ding Q;Chen S;Zhan J
抗体-药物偶联（ADC）是靶向癌症治疗的一个里程碑，它包括与细胞毒性药物化学连接的单克隆抗体。ADC的内化通过网格蛋白介导的内吞作用、小泡介导的内吞作用和胞饮作用发生。结合策略、内吞作用和细胞内运输优化、连接物和药物化学对研究人员成功根除肿瘤细胞提出了巨大的挑战。这种内吞作用和细胞内运输的创造性最近为开发治疗癌细胞的特异性抗体和adc提供了相当大的动力。有效地强调内吞作用和细胞内运输途径，设计有效的工程偶联物和生物实体，极大地促进了癌症治疗的有效治疗。目前的研究阐述了ADC的内吞作用和细胞内运输、蛋白质和卸载中的连接体策略，并简明地评估了实际应用的ADC。
Antibody–drug conjugate (ADC) is a milestone in targeted cancer therapy that comprises of monoclonal antibodies chemically linked to cytotoxic drugs. Internalization of ADC takes place via clathrin-mediated endocytosis, caveolae-mediated endocytosis, and pinocytosis. Conjugation strategies, endocytosis and intracellular trafficking optimization, linkers, and drugs chemistry present a great challenge for researchers to eradicate tumor cells successfully. This inventiveness of endocytosis and intracellular trafficking has given considerable momentum recently to develop specific antibodies and ADCs to treat cancer cells. It is significantly advantageous to emphasize the endocytosis and intracellular trafficking pathways efficiently and to design potent engineered conjugates and biological entities to boost efficient therapies enormously for cancer treatment. Current studies illustrate endocytosis and intracellular trafficking of ADC, protein, and linker strategies in unloading and also concisely evaluate practically applicable ADCs.